Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Irinotecan, Oxaliplatin and Cetuximab for Pancreatic Cancer
NCT00871169Phase 2Completed
- Sponsor
- New Mexico Cancer Research Alliance
- Start
- Oct 2008
- Primary completion
- Apr 2015
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and oxaliplatin in pancreatic cancer (PC), sponsored by New Mexico Cancer Research Alliance. Primary endpoint: Overall Response Rate at 2 years. Started Oct 2008; status: completed.
02
Drugs
KL-140irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00871169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00871169.